Cargando…
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
High levels of expression of glycoprotein non-metastatic B (gpNMB) in triple negative breast cancer (TNBC) and its association with metastasis and recurrence make it an attractive target for therapy with the antibody drug conjugate, glembatumumab vedotin (CDX-011). This report describes the developm...
Autores principales: | Marquez-Nostra, Bernadette V., Lee, Supum, Laforest, Richard, Vitale, Laura, Nie, Xingyu, Hyrc, Krzysztof, Keler, Tibor, Hawthorne, Thomas, Hoog, Jeremy, Li, Shunqiang, Dehdashti, Farrokh, Ma, Cynthia X., Lapi, Suzanne E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732808/ https://www.ncbi.nlm.nih.gov/pubmed/29262642 http://dx.doi.org/10.18632/oncotarget.22228 |
Ejemplares similares
-
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
por: Massicano, Adriana V. F., et al.
Publicado: (2018) -
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
por: Fang, Hanyi, et al.
Publicado: (2021) -
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021) -
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021) -
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer
por: Li, Ziqi, et al.
Publicado: (2022)